Denali Therapeutics Inc. (DNLI) stock

DNLINasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 6/30

$18.74−0.15 (-0.79%)

Close on Nov 13, 2026Market cap $3.00BP/E –Yield –

Denali Therapeutics price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Denali Therapeutics's price to sales ratio was 11.8× on Jul 31, 2024, against 38.3× a year earlier. Over the last 5 years it ranged from 6.5× to 426.7×, with a median of 28.9×.

Price to Sales Ratio at the end of each year

Period	Period end	Value	Change (pts)
2024	Jul 31, 2024	11.8×	+3.1
2023	Dec 29, 2023	8.7×	−22.4
2022	Dec 30, 2022	31.1×	+15.7
2021	Dec 31, 2021	15.4×	−411.3
2020	Dec 31, 2020	426.7×	+415.4
2019	Dec 31, 2019	11.3×	–

Where these numbers come from

Parsed from the XBRL in Denali Therapeutics's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is DNLI.

Compare: DNLI vs VYGR · DNLI vs ALEC · DNLI vs PASG · DNLI vs BIIB · DNLI vs MGTX

Company	Revenue	Growth
BIIB	$10.30B	+2.3%
MGTX	$401.91M	+1365.9%
ALEC	$173.47M	+151.2%
VYGR	$25.11M	-19.8%
DNLI	$0	–
PASG	–	–

Company

Next earnings (est.): Feb 25, 2027, during market hours
Exchange: Nasdaq
Industry: Biological Products, (No Diagnostic Substances)
Fiscal year ends: December 31
Employees: 503
Held by institutions: 97.7%
Auditor: Ernst & Young LLP
SEC CIK: 1714899

Advertisement
300 × 250

See a number that looks wrong?

Denali Therapeutics price to sales ratio

Price to Sales Ratio at the end of each year

More Denali Therapeutics figures